Gemtuzumab Ozogamicin is a promising post-remission therapy for acute myeloid leukemia

Leukemia Research

Volumn 33, Issue 4, 2009, Pages 565-566

  El Kinge, Abdul Rahman ^a   Hatoum, Hassan A ^a   Mahfouz, Rami A ^a   Otrock, Zaher K ^a   Jabbour, Elias ^b   Kantarjian, Hagop ^b   Bazarbachi, Ali ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN; GEMTUZUMAB OZOGAMICIN; IDARUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ANAMNESIS; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; CASE REPORT; CHROMOSOME ANALYSIS; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; FEMALE; HUMAN; LABORATORY TEST; LETTER; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RECURRENT DISEASE; TREATMENT OUTCOME; TREATMENT RESPONSE;

AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL;

EID: 60249093271     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.05.006     Document Type: Letter

References (7)

1. Zein N., Poncin M., Nilakantan R., and Ellestad G.A. Calicheamicin gamma 1I and DNA: molecular recognition process responsible for site-specificity. Science 244 (1989) 697-699
2. Sievers E.L., Appelbaum F.R., Spielberger R.T., Forman S.J., Flowers D., Smith F.O., et al. Antibody-targeted chemotherapy of acute myeloid leukemia using an anti-CD33 calicheamicin immunoconjugate, gemtuzumab ozogamicin. Biol Ther Leuk 1 (2000) 4-7
3. Legrand O., Perrot J.Y., Baudard M., Cordier A., Lautier R., Simonin G., et al. The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score. Blood 96 (2000) 870-877
4. Keating M.J., Kantarjian H., Smith T.L., Estey E., Walters R., Andersson B., et al. Response to salvage therapy and survival after relapse in acute myelogenous leukemia. J Clin Oncol 7 (1989) 1071-1080
5. Hiddemann W., Martin W.R., Sauerland C.M., Heinecke A., and Buchner T. Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia. Leukemia 4 (1990) 184-188
6. Davis C.L., Rohatiner A.Z., Lim J., Whelan J.S., Oza A.M., Amess J., et al. The management of recurrent acute myelogenous leukaemia at a single centre over a fifteen-year period. Br J Haematol 83 (1993) 404-411
7. Larson R.A., Boogaerts M., Estey E., Karanes C., Stadtmauer E.A., Sievers E.L., et al., Mylotarg Study Group. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia 16 (2002) 1627-1636